Tactiva, an immuno-oncology spinout of Roswell Park Comprehensive Cancer Center and based at University of Buffalo, will use the funding to drive its development program.

Kidney disease drug developer Variant has raised $10m from new strategic partner Incon in connection with a distribution agreement.

Praktikertjänst-backed anti-cancer therapy developer Aprea Therapeutics has now raised more than $100m of funding.

Karolinska Institute-founded anti-cancer therapy developer Aprea Therapeutics has now raised more than $100m of funding.

Lilly Asia Ventures has contributed to a $35m funding round for Elpiscience which has brought its overall funding to $55m.

Asahi Kasei has supplied $1m in a series A extension to bring the total of the series A round, already backed by GC, to $10.5m.

Each Friday the Global Corporate Venturing Deal Net rounds up the week’s smaller deals and tracks the emerging companies accessing corporate funds.

University of Twente-founded MyLife Technologies will commercialise a microneedle-based dermal patch for administering therapeutic compounds.

The diabetes treatment company backed by Johnson & Johnson and WL Gore & Associates has secured commitments for $80m in series D capital, with the money supplied across two tranches.

Standford-StartX Fund has taken part in a $10m series B round for Prescient Surgical, which was led by Baxter Ventures.